Antitumor effect of cytogenin against IMCcarcinoma in mice was investigated. Since cytogenin did not show cytotoxicity against tumor cells in vitro at 50 //g/ml and toxicity at more than 2,000 mg/kg i.p., it was considered that the antitumor effect is due to host mediated events. Cytogenin showed antitumor activity against a syngeneic murine transplantable tumor, IMC carcinoma by oral administration depending upon schedule of administration. The optimumeffect was observed by the administration starting day 8 after transplantation of tumor cells, every other day for 10 times or every 2nd day for 7 times. The antitumor effect was reduced in immunosuppressed mice given anti-asialo GM1serum and in athymic mice, but not in mice irradiated with X ray. The antitumor effector cells activated by cytogenin were determined to be macrophages and T cells.
Antitumor effect of cytogenin against IMCcarcinoma in mice was investigated. Since cytogenin did not show cytotoxicity against tumor cells in vitro at 50 //g/ml and toxicity at more than 2,000 mg/kg i.p., it was considered that the antitumor effect is due to host mediated events. Cytogenin showed antitumor activity against a syngeneic murine transplantable tumor, IMC carcinoma by oral administration depending upon schedule of administration. The optimumeffect was observed by the administration starting day 8 after transplantation of tumor cells, every other day for 10 times or every 2nd day for 7 times. The antitumor effect was reduced in immunosuppressed mice given anti-asialo GM1serum and in athymic mice, but not in mice irradiated with X ray. The antitumor effector cells activated by cytogenin were determined to be macrophages and T cells.
Cytogenin was found in cultured broth of Streptoverticillium eurocidicum MI43-37F11 as an antitumor antibiotic exhibiting antitumor activity against Ehrlich carcinoma in mice by oral administration1}.
Since cytogenin did not show cytotoxicity at 50 //g/ml against cultured tumor cells and acute toxicity to mice at more than 2,000mg/kg, i.p., it has been considered that the antitumor activity might be due to host mediated events. Therefore, we investigated the antitumor activity of cytogenin against a syngeneic murine transplantable tumor, IMC carcinoma, in normal and immunosuppressed mice and its effect on generation of antitumor effector cells.
Materials and Methods

Mice
CDFXmice (female, 6 weeks old) were purchased from Charles River Japan Inc. (Kanagawa, Japan), and were maintained under specific pathogen-free conditions at 23.0+ 1°C and 55±5% humidity. Balb/c nu/nu(-) mice (female, 6 weeks old) were purchased from Japan SLC Inc. (Shizuoka, Japan), and were kept in a clean rack under the conditions mentionedabove. These mice were used for experiments at 8 to 10 weeks old. Antitumor effector cells were assessed by a Winnassay according to the method described in previous report3).
Briefly, peritoneal exudate cells (PEG) and spleen cells were collected from tumor bearing mice on day 31 after tumor inoculation and splenic T cells were prepared by the methods using nylon wool column as reported previously4). PEC, spleen cells and splenic T cells were admixedwith 5 x 105 tumorcells ataratio of20: 1, 20: 1 and 2: 1, respectively. Then, 0.1ml of the mixture was inoculated s.c. to CDFimice and the antitumor activity was assessed by measuring tumor weight on day 32 after the inoculation.
Results
Antitumor activity of cytogenin against IMCcarcinomaon different schedules is shown in Table 1 . The optimum activity was observed on the schedule starting day 8 after tumor inoculation although the effect was shown slightly in daily treatment on days 1 to 7, but it was not significant in this tumor system. The effect in every 2nd day was better than that in other schedules. The dose response on the schedule in every 2nd day is shown in Fig. 1 . The administration ofcytogenin at 0.39 to 6.25 mg/kg p.o. showed a significant antitumor effect with a bell-shaped dose response curve. In this case, the most effective dose was 1.56mg/kg. The antitumor activity of cytogenin at 1.56mg/kg in every 2nd day starting day 8 after tumor inoculation was monitored.
As shown in Fig. 2 , cytogenin retarded the tumor growth in days 14 to 32 significantly. In immunocompromisedmice, the antitumor effect of cytogenin was examined. As shown in Table 2, in comparison to normal mice, the antitumor effect was reduced in mice treated with anti-asialo GM1serum and in athymic mice but not in mice irradiated with X ray. Since results shownabove indicated that the antitumor 1 x 106 IMCcarcinoma cells were inoculated sc to CDFi mice on day 0. Cytogenin was administered po from day 8 (Q2D x 7). Mean tumor weight were measured on day 31. *P<0.05, **P<0.01 against control group. 1 x 106 IMCcarcinoma cells were inoculated sc to CDF! mice on day 0. Cytogenin (1.56mg/kg) was administered po from day 8 (Q2Dx7). *** /><0.001 against control group. b Cytogenin (1.56mg/kg) was administered po from days 8 to 26 every 2nd day after tumor inoculation. c Tumorweight were measured on day 35 after tumor inoculation.
d (Cytogenin treated group/Non-treated group) x 100.
e T cell: IMC carcinoma, 2: 1. * P<0.05 and ** P<0.01 against non-treated group.
effect of cytogenin is host mediated, the antitumor effector cells activated by cytogenin were investigated. As shown in Table 3 , PEC and splenic T cells obtained from mice given cytogenin had significant antitumor activity against that of non-treated tumor bearing mice.
Discussion
Cytogenin was found in products of Streptoverticillium eurocidicum MI43-37F11 as an antitumor antibiotic exhibiting antitumor effect by oral administration against an allogenic murine solid tumor, Ehrlich carcinoma.
Since cytogenin did not show cytotoxicity on cultured murine and humantumor cells at 50/zg/ml and acute toxicity to mice at 2,000mg/kg i.p., it was considered that the antitumor activity of cytogenin might be due to host mediated events. Thus, we investigated the antitumor activity against a syngeneic murine tumor in detail. The antitumor activity of cytogenin against IMC carcinoma was strictly dependent on schedule as well as other low molecular immunomodulators such as ubenimex5), forphenicinol6) and conagenin7). The most effective schedule showed that the administration should be starting day 8 after tumor inoculation. It can be considered that cytogenin may be effective in activating concomitant immunity induced in tumor bearing mice.
It was supported that the antitumor effect of cytogenin reduced markedly in immunocommpromised mice treated with anti-asialo GM1serum and in athymic mice although it did not reduced in mice irradiated with X ray. Since those mice except mice irradiated with X ray could not be induced concomitant tumor immunity after transplantation of tumor cells and could not generate antitumor effector cells, the antitumor activity of cytogenin was not shown. It is of note that the antitumor activity of cytogenin did not reduce in mice irradiated with X ray. It is well known although X ray irradiation affects bone marrow cells, it can be protected by some cytokines like IL-18'9). It was reported that cytogenin enhanced monokine production of macrophages1}.
Furthermore, it will be reported that cytogenin modulates macrophage functions to stimulate IL-la production10). In this context, cytogenin might be effective in protecting dysfunction of bone marrow cells affected by X ray irradiation and might protect the generation of antitumor effector cells. It will be reported that cytogenin has the radio and chemoprotective activity in treatment of tumor bearing mice witji antitumor agents. Antitumor effector cells activated in mice given cytogenin was determined. As shown in Table 3 , the antitumor effect was detected in PEC and T cells. As reported7'1 1}, in IMCcarcinoma bearing mice cytotoxic T cells (CTL) were generated and IMC carcinoma cells were sensitive to CTLand macrophages but not NK cells. In this case, the activation ofmacrophagesleads to stimulate generation of CTL in tumor-bearing mice.
From above mentioned results, it can be concluded that cytogenin exerts antitumor effect by its immunomodulating activity exhibiting activation or modulation of macrophages.
